Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L Berry; Francis L Munier; Brenda L Gallie; Ashley Polski; Sona Shah; Carol L Shields; Dan S Gombos; Kathleen Ruchalski; Christina Stathopoulos; Rachana Shah; Rima Jubran; Jonathan W Kim; Prithvi Mruthyunjaya; Brian P Marr; Matthew W Wilson; Rachel C Brennan; Guillermo L Chantada; Murali M Chintagumpala; A Linn Murphree

doi:10.1002/pbc.28964

Response criteria for intraocular retinoblastoma: RB-RECIST

Pediatr Blood Cancer. 2021 May;68(5):e28964. doi: 10.1002/pbc.28964. Epub 2021 Feb 23.

Authors

Jesse L Berry^{1

2}, Francis L Munier³, Brenda L Gallie^{4

5

6}, Ashley Polski^{1

2}, Sona Shah^{1

2}, Carol L Shields⁷, Dan S Gombos⁸, Kathleen Ruchalski⁹, Christina Stathopoulos³, Rachana Shah¹⁰, Rima Jubran¹⁰, Jonathan W Kim^{1

2}, Prithvi Mruthyunjaya¹¹, Brian P Marr¹², Matthew W Wilson^{13

14}, Rachel C Brennan¹⁵, Guillermo L Chantada^{16

17

18}, Murali M Chintagumpala¹⁹, A Linn Murphree^{1

2}

Affiliations

¹ The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.
² USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
³ Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
⁴ Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Ophthalmology & Vision Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
⁶ Departments of Molecular Genetics & Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
⁷ Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
⁸ Department of Head & Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁹ Department of Radiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
¹⁰ Cancer and Blood Disease Institute at Children's Hospital Los Angeles, Los Angeles, California, USA.
¹¹ Department of Ophthalmology, Stanford Byers Eye Institute, Palo Alto, California, USA.
¹² Department of Ophthalmology, Columbia University Medical Center, New York, New York, USA.
¹³ Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
¹⁴ Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁵ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁶ Hemato-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina.
¹⁷ Pediatric Hematology & Oncology, Hospital Sant Joan de Deu, Barcelona, Spain.
¹⁸ Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
¹⁹ Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.

Abstract

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response-such as progression-free survival-to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

Keywords: clinical trials; imaging; ocular oncology; response criteria; retinoblastoma; ultrasonography.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Multimodal Imaging / methods
Response Evaluation Criteria in Solid Tumors*
Retinal Neoplasms / diagnostic imaging*
Retinoblastoma / diagnostic imaging*

Abstract

Publication types

MeSH terms

Grants and funding